Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687922 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL988286 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7094797 | 0.88 | SIGMAR1 (0.78) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9047802 | 0.86 | SIGMAR1 (0.76) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9048214 | 0.83 | SIGMAR1 (0.70) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9050714 | 0.81 | SIGMAR1 (0.67) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9046003 | 0.80 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9049352 | 0.80 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7698474 | 0.78 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7095248 | 0.74 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | SIGMAR1 4650/4885MEN1 3426/4885KMT2A 2736/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | SIGMAR1 4781/4885MEN1 2224/4885KMT2A 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.